Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:36:58 2024-04-29 am EDT			5-day change	1st Jan Change
3.025 ^USD	+2.89%		-3.97%	+30.39%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 19	JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	MT

Mersana Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 07, 2023 at 08:43 am EST

Mersana Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 41.66 million compared to USD 59.81 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.61 a year ago.
For the nine months, net loss was USD 152.13 million compared to USD 159.29 million a year ago. Basic loss per share from continuing operations was USD 1.33 compared to USD 1.75 a year ago.

Latest news about Mersana Therapeutics, Inc.

North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	Mar. 19	MT
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Truist Securities Upgrades Mersana Therapeutics to Buy From Hold, Price Target is $9	Feb. 29	MT
Guggenheim Upgrades Mersana Therapeutics to Buy From Neutral, Price Target is $7	Feb. 29	MT
Wedbush Upgrades Mersana Therapeutics to Outperform From Neutral, Notes Increased Confidence in Program; Adjusts PT to $7 From $2	Feb. 29	MT
Transcript : Mersana Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q4 Revenue $10.7M, vs. Street Est of $14.8M	Feb. 28	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Transcript : Mersana Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	Jan. 11
Mersana Therapeutics Gears Up for Milestones in Cancer Drug Trials	Jan. 05	MT
Mersana Therapeutics, Inc. Announces Business Updates	Jan. 05	CI
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
North American Morning Briefing : China Outlook -2-	Dec. 05	DJ
Citigroup Upgrades Mersana Therapeutics to Buy From Neutral, Raises Price Target to $5 From $1	Dec. 04	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Transcript : Mersana Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Mersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer Treatment	23-10-31	DJ
Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I Trial	23-10-31	DJ
Mersana Therapeutics, Inc. Announces FDA Has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056	23-10-31	CI
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from S&P Biotechnology Select Industry Index	23-09-18	CI
Mersana Therapeutics Names Martin Huber as Chief Executive	23-09-06	MT
Mersana Therapeutics Announces Management Changes	23-09-06	CI
Mersana Therapeutics, Inc. Announces Chief Executive Officer Changes	23-09-06	CI

Chart Mersana Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Mersana Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.94 USD

Average target price

6.5 USD

Spread / Average Target

+121.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MERSANA THERAPEUTICS, INC.	+30.39%	360M
VERTEX PHARMACEUTICALS INCORPORATED	-2.33%	103B
REGENERON PHARMACEUTICALS, INC.	+1.94%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.29%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-12.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+4.36%	13.68B
SAREPTA THERAPEUTICS, INC.	+35.54%	12.17B

Bio Therapeutic Drugs